Q2 FY27 · Ended Sep 30, 2026 · View SEC filing
Specialty is growing four times as fast as distribution
Oncology & Multispecialty grew 24.4% against 5.6% for drug distribution, shifting McKesson toward specialty drugs and physician services.
For investorsWhat the wider margin depends on from here
For foundersFrom shipping drugs to running care: the move up the value chain
Revenue rose 7.6% but operating income rose 14.0%, because operating costs grew more slowly than the gross profit that pays for them.
Operating income rose 14.0%, but McKesson's own net income rose 9.7% as interest and minority owners' shares grew faster.
Operating cash flow ran at 2.5 times net income this quarter, after a negative first quarter, so single quarters mislead.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes McKesson from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.